- AUD/USD benefits from the recent recovery in risks.
- Gilead’s remdesivir is getting noticeable success in clinical trials.
- US dollar strength, risk-off dominated market mood earlier.
- China's data, mainly the GDP, will be the key to watch while virus updates could keep markets entertained.
AUD/USD cheers the success of Gilead’s remdesivir clinical trials while rising to 0.6365, up 0.60% on a day, during the early Friday morning in Asia. In doing so, the Aussie pair bucks the previous day’s downbeat performance, portrayed mainly due to the broad US dollar strength and risk-off, while waiting for China’s key data.
Following the CNBC news suggesting the Gilead Life Science’s remdesivir is getting a huge success ratio during the clinical trials, markets dumped the previous risk-off with the S&P 500 ETF surging 2.0%.
Earlier, Wall Street managed to avoid losses with US President Donald Trump pushing for the phased re-open of the economy but the Treasury yields remain on the back foot amid worries concerning the coronavirus (COVID-19) crisis.
The pandemic issue remains center to market performance as there have been more than two million confirmed cases and the US death toll nears 31,000. This pushes New York to extend the lockdown, with Japan also announcing national emergency, but Switzerland bucks the trend to cite the restrictions’ exit measures. On Thursday, Aussie PM Scott Morrison also signaled for an exit strategy but also said, “need to be prepared for very sobering economic news in the months ahead.”
While the recent updates concerning the cure are likely to help the Aussie pair, major attention will be on China’s first quarter (Q1) GDP and March month Industrial Production, coupled with Retail Sales, figures. Although forecasts suggest downbeat figures for each of the key economic indicators, outcomes from the dragon nation have recently surprised markets. Hence, any such repetition of the surprises could offer an additional boost to the present risk reset, also propelling the Aussie quote.
Failure to provide a sustained break below the monthly support-line, currently at 0.6315, pushes the pair towards confronting a 50-day SMA level of 0.6365. Though, 0.6400 and Wednesday’s high near 0.6445 hold the gate for further upside. Alternatively, downside below 0.6315 could revisit the March-end top near 0.6215/10.
Additional important levels
|Today last price||0.6358|
|Today Daily Change||39 pips|
|Today Daily Change %||0.62%|
|Today daily open||0.6319|
|Previous Daily High||0.6444|
|Previous Daily Low||0.6284|
|Previous Weekly High||0.6369|
|Previous Weekly Low||0.5991|
|Previous Monthly High||0.6686|
|Previous Monthly Low||0.5509|
|Daily Fibonacci 38.2%||0.6345|
|Daily Fibonacci 61.8%||0.6383|
|Daily Pivot Point S1||0.6254|
|Daily Pivot Point S2||0.6188|
|Daily Pivot Point S3||0.6093|
|Daily Pivot Point R1||0.6414|
|Daily Pivot Point R2||0.6509|
|Daily Pivot Point R3||0.6575|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.